Anne-Claire Hardy-Bessard
Overview
Explore the profile of Anne-Claire Hardy-Bessard including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
49
Citations
835
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Joly F, Bazan F, Garbay Decoopman D, Garbay D, Ouldbey Y, Follana P, et al.
JNCI Cancer Spectr
. 2024 Dec;
9(1).
PMID: 39673810
Background: Maintenance niraparib at an individualized starting dose (ISD) is established in platinum-sensitive recurrent ovarian cancer (PSROC). However, patients' perspectives on the burden of prolonged maintenance therapy have not been...
2.
Giacchetti S, Laas E, Bachelot T, Lemonnier J, Andre F, Cameron D, et al.
EBioMedicine
. 2024 May;
104:105141.
PMID: 38718683
Background: Circadian rhythms regulate cellular physiology and could influence the efficacy of endocrine therapy (ET) in breast cancer (BC). We prospectively tested this hypothesis within the UNIRAD adjuvant phase III...
3.
Lorusso D, Mouret-Reynier M, Harter P, Cropet C, Caballero C, Wolfrum-Ristau P, et al.
Int J Gynecol Cancer
. 2023 Dec;
34(4):550-558.
PMID: 38129136
Objective: In the PAOLA-1/ENGOT-ov25 trial (NCT02477644), adding maintenance olaparib to bevacizumab provided a substantial progression-free survival benefit in patients with newly diagnosed advanced ovarian cancer and homologous recombination deficiency (HRD)-positive...
4.
Martinez A, Chargari C, Kalbacher E, Gaillard A, Leary A, Koskas M, et al.
Bull Cancer
. 2023 Aug;
110(6S):6S20-6S33.
PMID: 37573036
Recommendations for clinical practice, Nice/Saint-Paul-de-Vence 2022-2023: Management of localized endometrial cancer Endometrial cancer is the most frequent gynecological cancers in industrialized countries and its incidence increases. The newmolecularclassification allows determination...
5.
Abida W, Campbell D, Patnaik A, Bryce A, Shapiro J, Bambury R, et al.
Eur Urol
. 2023 Jun;
84(3):321-330.
PMID: 37277275
Background: Initial TRITON2 (NCT02952534) results demonstrated the efficacy of rucaparib 600 mg BID in patients with metastatic castration-resistant prostate cancer (mCRPC) associated with a BRCA1 or BRCA2 (BRCA) or other...
6.
Lequesne J, Joly F, Peron J, Ray-Coquard I, Hardy-Bessard A, Selle F, et al.
J Natl Compr Canc Netw
. 2023 May;
21(5):473-479.e4.
PMID: 37156482
Background: Current standards for toxicity reporting do not fully capture the impact of adverse events (AEs) on patients' quality of life (QoL). This study aimed to evaluate the association between...
7.
Merviel P, Rebahi C, James P, Kergastel I, Bourhis-Guizien F, Conan-Charlet V, et al.
Clin Case Rep
. 2023 Mar;
11(3):e7130.
PMID: 36992666
There are less than ten cases of deep endometriosis degeneration in the literature. The duration of endometriosis, the ovarian stimulation, the perimenopause and the obesity exposes the woman to an...
8.
Bidard F, Hardy-Bessard A, Delaloge S
Lancet Oncol
. 2023 Jan;
24(1):e4.
PMID: 36603926
No abstract available.
9.
Bailleux C, Arnaud A, Frenel J, Chabaud S, Bachelot T, You B, et al.
Breast Cancer
. 2023 Jan;
30(2):315-328.
PMID: 36602669
Background: The objective of the CHEOPS trial was to assess the benefit of adding aromatase inhibitor (AI) to metronomic chemotherapy, oral vinorelbine, 50 mg, three times a week for pre-treated,...
10.
Bidard F, Hardy-Bessard A, Dalenc F, Bachelot T, Pierga J, de La Motte Rouge T, et al.
Lancet Oncol
. 2022 Oct;
23(11):1367-1377.
PMID: 36183733
Background: In advanced oestrogen receptor-positive, HER2-negative breast cancer, acquired resistance to aromatase inhibitors frequently stems from ESR1-mutated subclones, which might be sensitive to fulvestrant. The PADA-1 trial aimed to show...